Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers
Top Cited Papers
- 4 October 2017
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 15 (1), 11-12
- https://doi.org/10.1038/nrclinonc.2017.156
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After ApprovalJAMA Internal Medicine, 2017
- Limitations Concerning the Association of Physician Sex and Patient Outcomes.JAMA Internal Medicine, 2017
- Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large National Private Claims DatabaseBone Marrow Transplantation, 2012
- Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?JNCI Journal of the National Cancer Institute, 2003